Introduction
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The recent FDA approval of vorapaxar ( Figure 1 ) for the "reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD)" marked an exciting development in the blockade of thrombin induced cellular activities. 1 Vorapaxar is a first-in- 15 class, highly potent protease activated receptor-1 (PAR-1) antagonist. PAR-1 is a seven transmembrane G-protein coupled receptor (7TM GPCR) expressed on many cell types throughout the body including platelets, endothelial cells and fibroblasts. It is agonised by an intramolecular mechanism following exposure to 20 thrombin. 2 It is an important receptor in the pathway towards thrombus formation and is associated with cardiovascular disease, as well as cancer and various fibrotic diseases.
2 PAR-1 antagonists could thus be used to treat a number of serious conditions. With this in mind, disclosed herein is the synthesis of 25 a series of novel vorapaxar analogues with particular focus on functionalisation at a position that has not been explored previously, i.e. the C-9 position. 
Results and Discussion
To begin, C-9-substituted vorapaxar analogues were to be synthesised on the basis of a published partial synthetic route towards natural product himbacine ( Figure 1 , and Schemes 1 & 2). [3] [4] [5] [6] [7] [8] This route was designed to provide access to analogues that 35 do not contain a carbamate group at C-7 and have a m-CF 3 on the aryl group rather a m-F substituent. These alterations will not affect the activity of the antagonist to any significant degree since they themselves were relatively late stage pharmacokinetic-based decisions made during the development of vorapaxar that were 40 shown to have little impact on potency, i.e. the carbamate was introduced as a means to improve oral delivery and the use of m-F in place of m-CF 3 was to reduce lipophilicity. 9 Moreover, the synthesis of analogues without these late stage changes, when trialling a new synthetic route to vorapaxar analogues, is if 45 anything a more sensible choice as it allows for direct comparison with the larger body of literature compounds made in the earlier stages of the development of vorapaxar. 9 Alteration(s) to the analogues described herein to aid pharmacokinetic properties without effecting potency can almost certainly be tuned into the 50 core, if need be, at a later stage.
Initially, trans-methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate ((±)-1) 4 and 5-methyl-2(5H)-furanone (2) 5 were synthesised using literature procedures. These were then reacted together using the conditions proposed by 55 Casey et al. to give (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (3) and (3R,3aS,4S,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (4) via kinetic resolution, albeit in low yields (12% and 5% respectively)
Scheme 1 Stereoselective tricycle synthesis
In order to furnish the desired C-9 functionalised vorapaxar analogues, the tert-butyl group of compounds 3/4 had to be replaced with the biaryl motif that is essential for the PAR-1 5 activity of vorapaxar. 6 To set about this, initially the tert-butyl group of the higher yielding tricycle (3) was removed using TFA/CH 2 Cl 2 (Scheme 2). The resulting acid was then coupled to ethanethiol using DCC and DMAP. The formed thioester (5) was next reduced using mild reducing conditions of triethylsilane and 10 catalytic palladium on carbon to give an aldehyde (6) . 7 Finally, Horner-Emmons conditions were used for reaction with biaryl phosphonate ester 7, which was prepared according to a literature procedure, 8 to form the desired C-9 functionalised vorapaxar analogues. Notably, prior to performing the Horner-Emmons 15 reaction, the aldehyde underwent partial epimerisation at the C-4 position. This conveniently afforded both C-4 epimers of the final C-9-keto-analogues (8 and 9, Scheme 2), and meant that the lower yielding tricycle 4 did not need to be carried through the synthesis to obtain compound 9.
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Scheme 2 Development of tricycle to give novel enantiomerically pure vorapaxar analogues 8 and 9
We noted from the outset that C-9-keto-analogues would have a useful carbonyl synthetic handle to allow the exploration of 25 SAR in a direction as yet unexplored on vorapaxar. To the best of our knowledge, there are no vorapaxar analogues with substitution at the C-9 position. As an initial foray into the novel SAR possibilities, the ketone of compound 8 was reduced to an hydroxyl group using NaBH 4 to give compounds 10 and 11
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( Figure 2 ) in 38% and 29% yield respectively. This was a significant transformation as it returned sp3 hybridisation at C-9, making the tricycle conformation more similar to that of vorapaxar. Additionally, compounds 8-11 would prove useful in exploring the effect on activity of sp2 vs. sp3 hybridisation at 35 C-9. The stereochemical assignment of compounds 8-11 was made on the basis of 1 H NMR coupling constants and 2D NMR analysis; see ESI for further details. 
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Next we used commercially available 2-(5H)-furanone in place of methyl-furanone 2 for reaction with trans-methyl 2-(2-(tertbutoxy)-2-oxoethyl)cyclohexanecarboxylate (±)-1 as a conduit to gain access to further distinct analogues of vorapaxar in terms of relative ring junction stereochemistry. The absence of the methyl stereochemical assignment at C-9a/C-3a compared with C-8a/C4a, i.e. (±)-14/15 and (±)-16, respectively. The enantiomeric pairs were then separated out into (+) and (-) enantiomers by chiral chromatography as the absolute stereochemistry of vorapaxar is believed to be important for PAR-1 potency. The results of the synthetic efforts gave 10 key compounds which were tested in a biological assay to determine their potency against PAR-1 (Figures 2-5, Table 1 ). The assay was based on 10 monitoring PAR-1 induced calcium flux in response to thrombin using FLIPR. 12 The novel analogues showed concentrationdependent antagonism in human lung fibroblasts vs. 10 nM thrombin as the agonist. The academic tool, RWJ-58259, 13 was used as a positive control and for a potency comparator.
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Enantiopure compounds 8-11 were tested initially ( Figure 4) . The most potent of these analogues, compound 9, gave an IC 50 of 0.5 µM. This meant that it had a similar potency to that of RWJ-58259 (IC 50 = 0.17 µM). Unfortunately, the potencies of the compounds did not quite match that of vorapaxar (IC 50 = 13 nM, 20 in this assay). It was interesting to note that the hydroxylanalogues (IC 50 : 10 = 72 µM and 11 = 120 µM) were less potent than the keto-analogues (IC 50 : 8 = 10.5 µM and 9 = 0.5 µM), indicating that the sp2 vs. sp3 hybridisation at C-9 was not critical to activity, and that (if anything) sp2 hybridisation may be 25 moderately preferred. 4 The average (n = 6) percentage inhibition observed upon the addition of thrombin (10 nM) to human lung fibroblasts in buffer preincubated with Fluo-4 NW dye mix and 0.003 -300 µM antagonist; 30 Compounds 8, 9, 10, Next, each of the enantiopure compounds obtained from (±)-14-15, were tested. In all cases, the compounds failed to reach 100% inhibition at a concentration of 30 µM. The concentration range was not extended to 300 µM, as seen with the compounds 35 8-11, because solubility issues were starting to be observed at 30 µM. As seen in the vorapaxar literature, one enantiomer was shown to be more potent than its pair (IC 50 : (-)- 14 
Conclusions
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In conclusion, an enantioselective route to himbacine-like tricycles has been adapted and developed to give a number of novel vorapaxar analogues which were tested biologically. The nanomolar potency found with compound (-)-16 is very significant because the novel scaffold has the potential for further 65 growth to investigate the SAR of vorapaxar, a first-in-class
16
PAR-1 antagonist drug. Whilst there is excellent recent work on C-7-spirocyclic analogues of vorapaxar, 14 and examples of functionalisation at other positions on the core, to the best of our knowledge these are the first PAR-1 active vorapaxar analogues with substitution at the C-9 position or with the differing relative 5 stereochemistry on the tricycle. Consequently, especially with readily functionalisable groups at the C-9 position, there is the prospect of developing further novel and potent PAR-1 inhibitors which could be used for the treatment of cancer and various fibrotic diseases.
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Experimental section
General Experimental
All solvents employed in this study were reagent grade. All reagents were purchased from Sigma-Aldrich, UK and Alfa Aesar, UK and used as received unless otherwise stated. All 15 reactions were magnetically stirred and monitored by thin layer chromatography (TLC) on pre-coated silica gel plates (254 μm) and/or by LCMS. Silica plates were initially examined under UV light and then developed using aqueous basic potassium permanganate stain. LCMS analysis was conducted on either 20 System A, an Acquity UPLC BEH C18 column (2.1 mm × 50 mm ID, 1.7 μm packing diameter) eluting with 0.1% formic acid in H 2 O (solvent A) and 0.1% formic acid in acetonitrile (MeCN) (solvent B), using the following elution gradient 0.0−1.5 min 3−100% B, 1.5−1.9 min 100% B, 1.9−2.0 min 3% B, at a flow 25 rate of 1 mL min−1 at 40 °C. The UV detection was an averaged signal from wavelength of 210 to 350 nm, and mass spectra were recorded on a mass spectrometer using alternate-scan electrospray positive and negative mode ionization (ES +ve and ES −ve); or System B, an Acquity UPLC BEH C18 column (50 mm × 2.1 30 mm ID, 1.7 μm packing diameter) eluting with 10 mM ammonium bicarbonate ((NH 4 )HCO 3 ) in H 2 O adjusted to pH10 with ammonia solution (solvent A) and MeCN (solvent B) using the following elution gradient 0−1.5 min 1−97% B, 1.5−1.9 min 97% B, 1.9−2.0 min 100% B at a flow rate of 1 mL min−1 at 40 35 °C. Preperative TLC was carried out using 20 cm x 20 cm glass TLC plates with a silica gel 60 matrix, supplied by EMD/Merck KGaA. Flash chromatography was carried out with silica gel (33-70 μm) supplied by Merck Co.. Automated column chromatography was performed using pre-packed silica gel 40 columns on a Flashmaster II. The Flashmaster II is an automated multiuser flash chromatography system, available from Argonaut Technologies Ltd, which utilizes disposable, normal phase, SPE cartridges (2−100 g). Chiral column chromatography was performed using various columns and conditions, see below for 45 details. Quoted yields refer to chromatographically and spectroscopically pure compounds unless otherwise stated.
1 H NMR spectra were recorded at 600 MHz with a Bruker AMX600. 13 C NMR spectra were recorded at 150 MHz. Chemical shifts (δ values) are reported in parts per million (ppm) whilst coupling 50 constants are reported in Hertz (Hz).
trans-Methyl
2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate (1)
n-BuLi (1.6 M in hexanes) (70.0 mL, 112 mmol) was added to a 55 stirred solution of DIPA (15.7 mL, 112 mmol) in anhydrous THF (30 mL) at -78 °C, under Ar. The solution was stirred at -78 °C for 20 mins. A solution of tert-butyl acetate (15.0 mL, 112 mmol) was added and stirring continued for 30 min at -78 °C. Next, a solution of (E)-methyl 7-iodohept-2-enoate (13.7 g, 51 mmol) in 60 anhydrous THF (15 mL) was added. The reaction mixture was stirred for a further 30 min at -78 °C. Finally, solid KOt-Bu (12.6 g, 112 mmol) was added and stirring continued for a further 1 h at -78 °C. The reaction mixture was quenched with sat. aq. NH 4 Cl (100 mL) and diluted with H 2 O (50 mL). An extraction into 65 EtOAc (2 x 100 mL) was completed and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to yield a crude pale yellow liquid. Multiple purifications by flash column chromatography (0-2% Et 2 
tert-Butyl
3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (3 and 4)
90 n-BuLi (2.5 M in hexane) (3.60 ml, 9.00 mmol) was added dropwise to a stirred solution of freshly distilled TMP (1.54 mL, 9.00 mmol) in anhydrous THF (10 mL) at -78 °C, under Ar. The solution was warmed to 0 °C and then re-cooled to -78 °C. 3R,3aR,4R,4aR,8aR,9aS) 3R,3aS,4aS,8aR,9aS)-3-Methyl-4-((E)-2-(5-(3 (3R,3aS,4R,4aS,8aR,9S,9aS )-9-hydroxy-3-methyl-4-((E)- anhydrous 2-MeTHF (40 mL) was added dropwise and stirring continued for 30 min at -78 °C. Next, furan-2(5H)-one (0.58 mL, 8.21 mmol) was added dropwise. The reaction mixture was stirred for a further 3 h, quenched with sat. aq. NH 4 Cl (50 mL) and diluted with H 2 O (25 mL). An extraction into EtOAc (2 x 50 55 mL) was done and the combined organic layers were washed with brine (30 mL), dried (hydrophobic frit) and concentrated in vacuo to yield a crude yellow oil with white precipitate. Purification by automated column chromatography (0-100% EtOAc/cyclohexane) yielded (3aS*,4R*,4aS*,8aS*,9aS*)-tert- 
